Five Prime Announces Fourth Quarter and Full Year 2016 Financial Results
"2016 was a year of tremendous progress in Five Prime's clinical and preclinical pipeline," said
2016 Business Highlights and Recent Developments
- Cabiralizumab (FPA008): an investigational antibody that inhibits CSF1R and has been shown to block the activation and survival of monocytes and macrophages. In the setting of advanced cancer, tumor-associated macrophages can inhibit the immune system's ability to eradicate the disease. In pigmented villonodular synovitis (PVNS), a CSF-1-driven tumor, the bulk of the tumor mass in joints is formed by the macrophages themselves. Five Prime and Bristol-Myers Squibb (BMS) have an exclusive worldwide collaboration agreement for the development and commercialization of cabiralizumab for these and potentially additional indications.
- Initiated Phase 1b portion of cabiralizumab/OPDIVO trial.
October 2016, Five Prime initiated the Phase 1b portion of the clinical trial evaluating the immunotherapy combination of cabiralizumab with the PD- 1 immune checkpoint inhibitor OPDIVO® (nivolumab) in multiple tumor types. Five Prime and BMS are evaluating the safety, tolerability and preliminary efficacy of the combination in advanced solid tumors, including non-small cell lung cancer, squamous cell carcinoma of the head and neck, pancreatic cancer, glioblastoma, renal cell carcinoma and ovarian cancer. Five Prime expects to complete enrollment in the current Phase 1b trial cohorts in the second half of 2017.
- Advanced the Phase 2 trial of cabiralizumab in patients with tenosynovial giant cell tumor (TGCT), also known as pigmented villonodular synovitis (PVNS).
Five Prime expects to complete enrollment of the Phase 2 trial of cabiralizumab in PVNS in the first half of 2017. Five Prime is evaluating clinical measures, including response rate, pain and range of motion in approximately 30 PVNS patients.
- Five Prime plans to seek regulatory guidance on a pivotal trial in diffuse PVNS.
- Five Prime plans to disclose clinical data from the cabiralizumab PVNS trial at the
American Society of Clinical Oncology(ASCO) 2017 Annual Meeting and from the cabiralizumab immuno-oncology trial in the second half of 2017.
- FPA144: an isoform-selective antibody in development as a targeted immuno-therapy for tumors that overexpress FGFR2b, a splice variant of a receptor for some members of the fibroblast growth factor (FGF) family. FPA144 has been engineered for enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) to increase direct tumor cell killing by recruiting natural killer (NK) cells. Five Prime retains global development
and commercialization rights to FPA144.
- Opened new gastric cancer cohorts and added a bladder cancer cohort in Phase 1 monotherapy trial of FPA144. Enrollment continues in the expansion portion of the trial, evaluating the safety, PK and efficacy of biweekly 15 mg/kg infusions of FPA144 in patients with gastric cancer whose tumors highly overexpress FGFR2b. During the third quarter of 2016, Five Prime added cohorts to evaluate FPA144 in patients with bladder cancer whose tumors overexpress FGFR2b and in patients with gastric cancer whose tumors express moderate or low levels of FGFR2b. Five Prime reported initial single-agent efficacy and safety data at the ASCO 2016 Annual Meeting and at the ASCO 2016 Gastrointestinal Cancers Symposium.
- Five Prime plans to seek regulatory guidance on a registrational path for FPA144 in combination with chemotherapy as an early-line gastric cancer therapy.
- Five Prime plans to disclose updated clinical data from the FPA144 program at the ASCO 2017 Annual Meeting.
- FP-1039: a protein drug designed to block FGF signaling. As a ligand trap, FP-1039 binds to and neutralizes a subset of FGF ligands (such as FGF2), preventing these growth-promoting and angiogenic proteins from reaching FGFR1 on the surface of tumor cells.
- Five Prime plans to make decisions on potential future development of FP-1039 in mesothelioma after data on objective response rate, disease control rate and progression-free survival are mature. Five Prime regained full rights to FP-1039 from GlaxoSmithKline (GSK) in
September 2016. GSK is completing the ongoing Phase 1b trial combining FP-1039 with 1st-line pemetrexed and cisplatin in untreated, unresectable mesothelioma. GSK concluded trial recruitment with 25 patients enrolled at the 15 mg/kg dose in June 2016, and continues to dose and follow patients.
- Five Prime plans to disclose clinical data from this program at the
European Society for Medical Oncology(ESMO) 2017 Congress.
- Five Prime unveiled three preclinical development candidates in IND-enabling studies at its R&D Day in
New York Cityin December 2016.
- FPA150 (anti-B7-H4)
-- An antibody designed for two mechanisms of action: to block an inhibitory T cell checkpoint pathway and to enhance killing of B7-H4-expressing tumors by ADCC.
-- Investigational New Drug (IND) application planned for the fourth quarter of 2017.
- FPA154 (GITR agonist antibody)
-- A tetravalent agonist antibody designed for greater GITR activation versus conventional antibodies. Conventional GITR agonist antibodies have two GITR binding sites while FPA154 has four.
-- IND application planned for the fourth quarter of 2017.
- FPT155 (CD80)
-- A natural, multi-targeting immune modulator that stimulates T cell responses through three critical pathways: CTLA4 blockade, CD28 agonism (without superagonism) and PD-L1 blockade that removes a potent inhibitory checkpoint.
-- IND planned in 2018.
- Progress in pre-clinical and research programs is on track for the company to achieve the goal of filing at least one IND application for a new molecule each year for the foreseeable future, beginning this year.
- Completed multiple immuno-oncology research screens to identify new targets and drug candidates. Five Prime's research team completed functional screens on CD8 T cells and regulatory T cells, as well as a comprehensive screen of all extracellular binding interactions in the "immunome," a defined subset of 700 extracellular proteins enriched for potential immune cell modulators. Five Prime conducted the screens to identify new immuno-oncology targets, which the company is prioritizing for further development
as targets for new drug candidates or drug candidates themselves, either as monotherapies or as part of rational combination regimens.
- Five Prime will feature three preclinical research poster presentations during the 2017
American Association for Cancer Research(AACR) Annual Meeting, April 1 - 5, 2017, in Washington, D.C.
Summary of Financial Results and Guidance:
- Cash Position. Cash, cash equivalents and marketable securities totaled
$421.7 millionon December 31, 2016compared to $517.5 millionon December 31, 2015. The decrease in year-end cash in 2016 was primarily attributable to net cash used in operations to advance the company's clinical and preclinical pipeline.
- Revenue. Collaboration and license revenue for the fourth quarter of 2016 was
$8.3 millioncompared to $363.3 millionfor the fourth quarter of 2015. During the fourth quarter of 2015, the company recognized the entire upfront payment of $350 millionas revenue under the cabiralizumab license and collaboration agreement with BMS. Collaboration and license revenue for the full year 2016 was $30.7 millioncompared to $379.8 millionfor the full year 2015.
- R&D Expenses. Research and development expenses for the fourth quarter of 2016 increased by
$8.2 million, or 39%, to $29.1 millionfrom $21.0 millionin the fourth quarter of 2015. Full year 2016 research and development expenses increased by $23.9 million, or 34%, to $94.1 millionin 2016 from $70.2 millionin 2015. These increases were primarily related to advancing the FPA144 program in a phase 1 clinical trial, advancing the cabiralizumab program in immuno-oncology and PVNS, and advancing our internal immuno-oncology preclinical and research activities.
- G&A Expenses. General and administrative expenses for the fourth quarter of 2016 increased by
$1.9 million, or 22%, to $10.5 millionfrom $8.6 millionin the fourth quarter of 2015. Full year 2016 general and administrative expenses were $35.8 million, an increase of $13.2 million, or 58%, from $22.6 millionin 2015. This increase was primarily due to increases in personnel related expenses, including stock-based compensation.
- Net Income (Loss). Net loss for the fourth quarter of 2016 was
$20.1 million, or $0.73per basic share and diluted share, compared to net income of $296.1 million, or $11.37per basic share and $10.63per diluted share, for the fourth quarter of 2015. Full year 2016 net loss was $65.7 million, or $2.44per basic share and diluted share, compared to net income of $249.6 million, or $9.73per basic share and $9.23per diluted share. These decreases in net income were primarily related to recognizing the 2015 upfront payment of $350 millionas revenue under the cabiralizumab license and collaboration agreement with BMS.
Cash Guidance. Five Prime
expects full-year 2017 net cash used in operating activities to be less than
Conference Call Information
Five Prime will host a conference call and live audio webcast today at
About Five Prime
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Five Prime's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements about (i) the timing of IND filings; (ii) the timing of initiation, progress and scope of clinical trials for Five Prime's product candidates, including regarding the completion of enrollment in such trials; (iii) Five Prime's full-year 2017 net cash used in operating activities; and (iv) the estimated amount of Five Prime's cash, cash equivalents and marketable securities at the end of 2017. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of Five Prime's collaborators to support or advance collaborations or product candidates, and unexpected litigation or other disputes. Other factors that may cause Five Prime's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Five Prime's filings with the
|Selected Balance Sheets Data|
|Balance Sheet Data:|
|Cash, cash equivalents and marketable securities||$||421,748||$||517,466|
|Total current liabilities (excluding deferred revenue)||24,591||61,859|
|Deferred revenue (in total, including short term portion)||32,006||48,777|
|Total stockholders' equity||391,575||433,206|
|Condensed Statements of Operations|
|(in thousands, except per share amounts)|
|For The Three Months |
| For The Year Ended|
|Collaboration and license revenue||$||8,262||$||363,341||$||30,691||$||379,801|
|Research and development||29,149||20,956||94,072||70,197|
|General and administrative||10,522||8,602||35,831||22,631|
|Total operating expenses||39,671||29,558||129,903||92,828|
|Operating income (loss)||(31,409||)||333,783||(99,212||)||286,973|
|Income (loss) before income tax||(30,763||)||333,938||(96,745||)||287,457|
|Income tax benefit (provision)||10,657||(37,810||)||31,048||(37,810||)|
|Net income (loss)||$||(20,106||)||$||296,128||$||(65,697||)||$||249,647|
|Basic net income (loss) per common share||$||(0.73||)||$||11.37||$||(2.44||)||$||9.73|
|Diluted net income (loss) per common share||$||(0.73||)||$||10.63||$||(2.44||)||$||9.23|
|Shares used to compute basic net income (loss) per common share||27,436||26,043||26,955||25,661|
|Shares used to compute diluted net income (loss) per common share||27,436||27,850||26,955||27,035|
Heather RoweInvestor Relations 415-365-5737 email@example.com Amy KendallCorporate Communications 415-365-5776 firstname.lastname@example.org
News Provided by Acquire Media